Enzyme and Metabolic Disorder Therapies: Adzynma (ADAMTS13, recombinant-krhn)
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization for Adzynma under the MassHealth UPPL for members receiving medical-benefit therapy and establishes eligibility, documentation, dosing, prescriber, and continuation requirements for congenital thrombotic thrombocytopenic purpura.
The review history describes the 2026 policy update as a formatting update.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.